FLAIR: Monthly Cabotegravir + Rilpivirine Non-Inferior to DTG/ABC/3TC at 48 Weeks
MAR 07, 2019 | MICHAELA FLEMING
The 48-week results of the FLAIR study indicate that the regimen of a monthly injection of long acting cabotegravir/rilpivirine is non-inferior to a regimen of oral dolutegravir/abacavir/lamivudine (DTG/ABC/3TC).
In an exclusive interview Contagion® spoke to Brian Woodfall, MD, global head of development at Janssen, about the new data (see video).
"The FLAIR and the ATLAS trials were 2 phase 3 trials of long-acting injectable cabotegravir plus rilpivirine and the really amazing thing about both of them is that they really tested a completely new paradigm in the treatment of HIV infection." Dr. Woodfall said.
"These are the first trials that have tested a regimen that provides the opportunity for more infrequent dosing. So, in this case an injection of each of those 2 antiretrovirals once a month," Dr. Woodfall added.
First Long-Acting Injectable Regimen (FLAIR) was designed to evaluate the 2-drug long-acting injectable regimen of the integrase strand transfer inhibitor (INSTI) cabotegravir and nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine. The investigational long-acting injectable is being developed to reduce dose frequency, pill taking, and drug exposures that are typical of current HIV treatment regimens.
For the phase 3, open-label, multicenter study, patients with HIV who were antiretroviral therapy treatment (ART)-naïve received induction therapy with oral DTG/ABC/3TC for 20 weeks. The participants with HIV 1- RNA <50 c/mL at 16 weeks were eligible to enter the maintenance phase of the trial. The trial enrolled 566 participants who were randomly assigned 1:1 to continue current therapy or switch to the long-acting injectable therapy.
At induction phase start, the median CD4 count was 444 cells/mm3, median VL was 4.4 log10 c/mL. The median age of the trial participants was 34 years, 22% were female and 74% were white.
The 283 participants in the long-acting arm received an oral lead in of 30 mg of cabotegravir + 25 mg of rilpivirine once daily for 4 weeks to evaluate tolerability, before receiving cabotegravir/rilpivirine as an intramuscular long-acting injectable therapy.
Six participants in the cabotegravir/rilpivirine arm (2.1%) and 7 in the DTG/ABC/3TC arm (2.5%) met the primary endpoint of viral load >50 c/mL at 48 weeks by US Food and Drug Administration snapshot algorithm (non-inferiority margin 6%).
Secondary endpoints included safety, tolerability, and confirmed virologic failure. The investigators indicate that the key secondary endpoint of HIV-1 RNA <50 c/mL was achieved by 93.6% of the cabotegravir/rilpivirine arm and 93.3% of the DTG/ABC/3TC arm.
Confirmed virologic failure was observed in 4 participants (1.4%) in the cabotegravir/rilpivirine; 3 had mutations in the NNRTI + INSTI domains and 1 was not tested. In the DTG/ABC/3TC arm, 3 confirmed virologic failures, none of which had INSTI resistance.
Among the participants in the cabotegravir/rilpivirine arm, the most common adverse event was injection site reactions, which were reported in 82% of the enrolled participants. The injection site reactions decreased in frequency over time, with 99% categorized as grade 1 or 2 events, with a median duration of 3 days.
The investigators also noted that of the 263 cabotegravir/rilpivirine arm participants completing an HIV Treatment Satisfaction Questionnaire at week 48, 99% reported being more satisfied with long-acting cabotegravir and rilpivirine compared with daily oral treatment.
The 48-week results of ATLAS indicate that the long-acting regimen of cabotegravir/rilpivirine was non-inferior to DTG/ABC/3TC and generally well tolerated, with few serious adverse events.
“Overall these results demonstrated the therapeutic potential of CAB+RPV injections, following short initial induction with oral DTG/ABC/3TC to achieve viral suppression,” the investigators concluded.
The study, “Long-Acting Cabotegravir + Rilpivirine for HIV Maintenance: FLAIR 48 Week Results,” was presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI), held March 4-7, 2019, in Seattle, Washington.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512